Healthequity (NASDAQ:HQY) had its target price boosted by investment analysts at Raymond James from $85.00 to $105.00 in a research report issued on Monday, September 10th. The brokerage presently has an “outperform” rating on the stock. Raymond James’ price objective points to a potential upside of 17.33% from the company’s previous close.
Several other equities analysts have also recently issued reports on HQY. KeyCorp boosted their price objective on Healthequity from $72.00 to $82.00 and gave the company an “overweight” rating in a report on Tuesday, June 5th. Oppenheimer lifted their price target on Healthequity from $68.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, June 5th. Zacks Investment Research lowered Healthequity from a “hold” rating to a “sell” rating in a research note on Wednesday, July 11th. SunTrust Banks lifted their price target on Healthequity from $70.00 to $85.00 and gave the company a “buy” rating in a research note on Tuesday, June 5th. Finally, ValuEngine upgraded Healthequity from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 22nd. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $93.08.
HQY stock traded down $1.08 on Monday, hitting $89.49. 616,624 shares of the company’s stock were exchanged, compared to its average volume of 618,960. Healthequity has a 12-month low of $42.92 and a 12-month high of $99.99. The company has a market cap of $5.86 billion, a price-to-earnings ratio of 165.72, a price-to-earnings-growth ratio of 3.28 and a beta of 1.47.
Healthequity (NASDAQ:HQY) last issued its quarterly earnings results on Tuesday, September 4th. The company reported $0.34 EPS for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.12. The company had revenue of $71.10 million during the quarter, compared to analysts’ expectations of $69.84 million. Healthequity had a return on equity of 12.58% and a net margin of 23.81%. The firm’s revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.27 EPS. Sell-side analysts predict that Healthequity will post 0.87 EPS for the current year.
In related news, Director Frank Medici sold 6,904 shares of the company’s stock in a transaction that occurred on Friday, July 13th. The stock was sold at an average price of $80.40, for a total value of $555,081.60. Following the transaction, the director now directly owns 17,649 shares in the company, valued at $1,418,979.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Darcy G. Mott sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $92.93, for a total value of $371,720.00. Following the completion of the transaction, the vice president now owns 96,100 shares in the company, valued at $8,930,573. The disclosure for this sale can be found here. Insiders sold 30,500 shares of company stock valued at $2,522,301 over the last 90 days. Company insiders own 4.00% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in Healthequity by 11.3% during the second quarter. BlackRock Inc. now owns 7,688,768 shares of the company’s stock worth $577,427,000 after purchasing an additional 777,915 shares in the last quarter. FMR LLC raised its stake in shares of Healthequity by 26.5% in the second quarter. FMR LLC now owns 3,410,542 shares of the company’s stock valued at $256,132,000 after acquiring an additional 715,441 shares in the last quarter. Carillon Tower Advisers Inc. raised its stake in shares of Healthequity by 751.9% in the second quarter. Carillon Tower Advisers Inc. now owns 752,482 shares of the company’s stock valued at $56,511,000 after acquiring an additional 664,157 shares in the last quarter. Brown Advisory Inc. acquired a new stake in shares of Healthequity in the first quarter valued at $29,553,000. Finally, Champlain Investment Partners LLC acquired a new stake in shares of Healthequity in the first quarter valued at $25,208,000. Hedge funds and other institutional investors own 96.94% of the company’s stock.
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.